title: A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
abstract: GH insensitivity due to GH receptor deficiency is a rare autosomal recessive condition, characterized by deletions or mutations of the GH receptor gene. Patients are refractory to both endogenous and exogenous GH, resulting in severe growth retardation. Therapy with recombinant human insulin-like growth factor-I (rhIGF-I) can bypass the defect in the GH receptor and potentially stimulate growth. We previously identified a genetically homogeneous group of patients in southern Ecuador, thus providing a patient base for a controlled clinical trial of rhIGF-I therapy. Seventeen prepubertal patients were entered in a randomized, double blind, placebo-controlled trial. Subjects received either a 12-month course of rhIGF-I (120 micrograms/kg, sc, daily) or 6 months of placebo followed by 6 months of rhIGF-I. Subjects receiving rhIGF-I showed a significant increase in growth rate, which was sustained over the 1-yr course of therapy (from 2.9 +/- 0.6 to 8.6 +/- 0.4 cm/yr). Incidents of hypoglycemia were equal in frequency in the placebo and rhIGF-I groups. One recipient of rhIGF-I developed papilledema, which resolved spontaneously. rhIGF-I therapy did not alter serum IGF-binding protein-3 concentrations. rhIGF-I treatment is effective in stimulating skeletal growth in GH receptor deficiency. Although the therapy proved to be safe, the potent metabolic actions of rhIGF-I and the persistently low levels of serum IGF carrier protein necessitate continued careful observation for side-effects.
authors.affiliation: Instituto Endocrinologia, Metabolismo, y Reproduccion, Quito, Ecuador.
authors.forename: J
authors.initials: J
authors.lastname: Guevara-Aguirre
authors.forename: O
authors.initials: O
authors.lastname: Vasconez
authors.forename: V
authors.initials: V
authors.lastname: Martinez
authors.forename: A L
authors.initials: AL
authors.lastname: Martinez
authors.forename: A L
authors.initials: AL
authors.lastname: Rosenbloom
authors.forename: F B
authors.initials: FB
authors.lastname: Diamond
authors.forename: S E
authors.initials: SE
authors.lastname: Gargosky
authors.forename: L
authors.initials: L
authors.lastname: Nonoshita
authors.forename: R G
authors.initials: RG
authors.lastname: Rosenfeld
mesh_terms: D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002352:Carrier Proteins / Q000097:blood; D002648:Child; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009752:Nutritional Status; D011986:Receptors, Somatotropin / Q000172:deficiency*; D011994:Recombinant Proteins; D013002:Somatomedins / Q000378:metabolism
chemical_list: D002352:Carrier Proteins; D018969:Insulin-Like Growth Factor Binding Proteins; D011986:Receptors, Somatotropin; D011994:Recombinant Proteins; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I